# colorectal cancer - claude-opus-4-8

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 25218
- Completion tokens: 9924
- Reasoning tokens: 0
- Total tokens: 35142
- API requests reported: 3
- Elapsed seconds: 276.419
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: Anthropic

---
# Multidimensional Interpretation of Prognostic Transcriptomic Signatures in Colorectal Cancer

## 1. Overall Biological Interpretation

The transcriptomic landscape reveals a prognostic architecture dominated by metabolic reprogramming, epithelial differentiation loss, and stromal remodeling. The 100-gene signature splits nearly evenly between risk (54 genes, HR>1) and protective (46 genes, HR<1) associations, suggesting bidirectional selective pressures operating during colorectal cancer progression.

Risk-associated genes converge on three mechanistic axes: (1) epithelial-mesenchymal plasticity and stromal activation (INHBB, SCARA3, DCBLD2, ZEB1-AS1), (2) pro-survival signaling and metabolic flexibility (AKT3, LRRC8A, PTPN14), and (3) regulatory RNA networks (MIR31HG, NR2F1-AS1). Protective genes cluster around (1) mitochondrial oxidative metabolism (ATP23, NDUFA9, CS, TIMM13, ATP5B), (2) epithelial differentiation programs (CDX2, MYO5B, TAPBPL, LGALS4), and (3) tumor suppressor networks (MYB, GADD45B, BCL2L14).

The signature reflects a prognostic trade-off: tumors retaining oxidative metabolism and differentiated epithelial identity show better survival, while those adopting glycolytic, dedifferentiated, and stromal-enriched phenotypes face worse outcomes. This pattern is consistent with consensus molecular subtypes in colorectal cancer, where mesenchymal and metabolically reprogrammed tumors demonstrate aggressive behavior.

---

## 2. Core Biological Programs

### **Program 1: Mitochondrial Oxidative Metabolism — Protective**

**Direction:** Protective (HR < 1)  
**Supporting genes:** ATP23 (HR=0.69, FDR=0.0066), NDUFA9 (HR=0.69, FDR=0.0086), CS (HR=0.75, FDR=0.0388), TIMM13 (HR=0.75, FDR=0.0394), MCCC2 (HR=0.74, FDR=0.0282), ILVBL (HR=0.72, FDR=0.0329), ATP5B, COA3  
**Pathway mapping:** Reactome: Respiratory electron transport, TCA cycle and respiratory electron transport; GO: mitochondrial respiratory chain complex assembly, aerobic respiration  
**Biological rationale:** Eight genes encode core components of oxidative phosphorylation and mitochondrial bioenergetics. ATP23 is a mitochondrial protease required for ATP synthase assembly; NDUFA9 is a Complex I subunit; CS catalyzes the first step of the TCA cycle; TIMM13 mediates mitochondrial protein import. Their coordinated protective effect indicates that tumors maintaining oxidative metabolism have better prognosis, consistent with the Warburg reversal hypothesis where retention of OXPHOS capacity limits aggressive phenotypes. Network evidence confirms CS interactions with ACSS2 and ILVBL, supporting metabolic coherence.

**Evidence strength:** Strong. Multiple independent mitochondrial genes with consistent direction and established functional relationships. GTEX confirms broad tissue expression (81/100 genes have records). PubMed record [17135288] validates ATP23's role in ATP synthase assembly.

**Limitations:** Mitochondrial gene expression may reflect tumor cellularity rather than per-cell OXPHOS activity. Protective association could indicate lower stromal content in differentiated tumors rather than direct metabolic causation. External cohort validation is unavailable.

---

### **Program 2: Epithelial Differentiation and Intestinal Identity — Protective**

**Direction:** Protective (HR < 1)  
**Supporting genes:** CDX2 (HR=0.75, FDR=0.0355), MYO5B (HR=0.75, FDR=0.0282), TAPBPL (HR=0.71, FDR=0.0192), LGALS4, AQP11, DNPEP (HR=0.73, FDR=0.0361), PXMP2 (HR=0.72, FDR=0.0276)  
**Pathway mapping:** GO: epithelial cell differentiation, apical protein localization; KEGG: proximal tubule bicarbonate reclamation (related to epithelial transport)  
**Biological rationale:** Seven genes maintain differentiated epithelial architecture. CDX2 is the master transcription factor for intestinal epithelial differentiation; literature [30631044] confirms CDX2 suppresses Wnt/β-catenin signaling and inhibits colon cancer proliferation. MYO5B mediates apical protein trafficking essential for polarized epithelia. TAPBPL regulates MHC class I antigen presentation, linking differentiation to immune visibility. The protective effect suggests tumors retaining intestinal differentiation programs have limited invasive capacity and better outcomes.

**Evidence strength:** Moderate-strong. CDX2's role is well-established in colorectal biology with direct literature support. Multiple genes converge on epithelial architecture, but fewer than the metabolic program. HPA tissue expression data available for 75/100 genes supports context-appropriate expression patterns.

**Limitations:** Differentiation markers may be passenger features of less aggressive tumors rather than causal protective factors. CDX2 expression heterogeneity within tumors is not captured by bulk transcriptomics. Some protective genes (PXMP2, DNPEP) have weaker mechanistic links to differentiation.

---

### **Program 3: TGF-β/Activin Signaling and Stromal Activation — Risk**

**Direction:** Risk-associated (HR > 1)  
**Supporting genes:** INHBB (HR=1.43, FDR=0.0011), SCARA3 (HR=1.38, FDR=0.0024), DCBLD2 (HR=1.41, FDR=0.0086), ITGBL1 (HR=1.30, FDR=0.0306), ADAMTS18  
**Pathway mapping:** KEGG: TGF-beta signaling pathway; GO: extracellular matrix organization, regulation of cell migration; Reactome: Extracellular matrix organization  
**Biological rationale:** Five genes drive stromal remodeling and TGF-β superfamily signaling. INHBB encodes inhibin beta B, an activin subunit promoting tumor-stroma interactions and immunosuppression; it shows the strongest risk association (HR=1.43, FDR=0.0011) with direct literature support [41992239] confirming high INHBB expression drives malignant phenotypes in colorectal cancer. SCARA3 is a scavenger receptor upregulated in cancer-associated fibroblasts. DCBLD2 regulates VEGF signaling and angiogenesis. The program reflects a mesenchymal, stroma-rich tumor microenvironment associated with metastatic potential and therapy resistance.

**Evidence strength:** Strong. INHBB has the most significant association in the entire dataset with direct colorectal cancer literature validation. Multiple genes converge on stromal biology with network support (ADAMTS18 in cellular_component GO terms). ClinVar records available for 83/100 genes provide genetic variant context.

**Limitations:** Stromal gene expression may originate from non-malignant cells, confounding tumor-intrinsic vs. microenvironmental contributions. The protective/risk dichotomy may reflect cellular composition rather than transcriptional programs within cancer cells. STRING provides only 42 edges for the full gene set, indicating incomplete network coverage.

---

### **Program 4: PI3K/AKT Signaling and Survival Pathways — Risk**

**Direction:** Risk-associated (HR > 1)  
**Supporting genes:** AKT3 (HR=1.32, FDR=0.0388), LRRC8A (HR=1.38, FDR=0.0250), PTPN14 (HR=1.36, FDR=0.0250), ABL2 (HR=1.30, FDR=0.0276)  
**Pathway mapping:** KEGG: Melanoma, Gastric cancer (both involve PI3K/AKT); GO: regulation of phospholipase C activity; Reactome: PI3K/AKT signaling  
**Biological rationale:** Four genes activate pro-survival and anti-apoptotic signaling. AKT3 is a serine/threonine kinase in the PI3K/AKT pathway, promoting cell survival and proliferation; its 7 probe representation in the dataset indicates robust detection. LRRC8A forms volume-regulated anion channels and regulates apoptosis resistance. PTPN14 is a protein tyrosine phosphatase with context-dependent oncogenic roles. The program reflects enhanced survival signaling enabling resistance to microenvironmental stress and therapy.

**Evidence strength:** Moderate. AKT3's oncogenic role is established, but the specific colorectal cancer prognostic context is less directly validated than INHBB. Multiple probes for AKT3 and PTPN14 (4 and 4 probes respectively) suggest technical robustness, but also raise concerns about probe-level heterogeneity. HumanBase network data available for 78/100 genes.

**Limitations:** PTPN14 shows "direction-conflict" annotation, indicating probe-level inconsistency that weakens confidence. PI3K/AKT is a common cancer pathway, reducing specificity. External cohort validation is absent. The program is less coherent than metabolic or differentiation programs, with genes having diverse primary functions beyond AKT signaling.

---

### **Program 5: Long Non-coding RNA Regulatory Networks — Risk**

**Direction:** Risk-associated (HR > 1)  
**Supporting genes:** MIR31HG (HR=1.31, FDR=0.0066), ZEB1-AS1 (HR=1.37, FDR=0.0086), NR2F1-AS1 (HR=1.31, FDR=0.0355), LINC00852 (suggested by literature [34342374])  
**Pathway mapping:** No direct pathway annotation (lncRNAs function through diverse mechanisms)  
**Biological rationale:** Three antisense/lncRNA genes regulate epithelial-mesenchymal transition and transcriptional programs. ZEB1-AS1 stabilizes ZEB1, a master EMT transcription factor suppressing E-cadherin. MIR31HG hosts microRNAs regulating differentiation. NR2F1-AS1 modulates nuclear receptor signaling. Literature [34342374] documents LINC00852's role in poor prognosis through miR-145-5p/KLF4 axis inhibition. The program reflects post-transcriptional regulatory layers maintaining dedifferentiated states.

**Evidence strength:** Weak-moderate. Individual lncRNA-cancer associations are documented, but their collective function as a coherent program is speculative. LncRNAs often have context-specific and cell-type-dependent effects, reducing generalizability. Only 3 genes have sufficient statistical evidence (FDR<0.05) for this program.

**Limitations:** LncRNA mechanisms are incompletely understood and may vary between patients. Their prognostic value may be indirect, reflecting broader transcriptional states rather than causal roles. Limited pathway annotation and network data (lncRNAs excluded from most protein-centric databases) prevent systematic validation. Direction-conflict annotation for some multi-transcript genes (LOC101929504, RBMX/SNORD61) indicates measurement ambiguity.

---

## Summary

The five programs represent hierarchical biological processes: metabolic state (Program 1) and differentiation status (Program 2) define the core tumor phenotype; stromal activation (Program 3) and survival signaling (Program 4) enable aggressive behavior; regulatory RNA networks (Program 5) stabilize these states post-transcriptionally.

Programs 1-3 have the strongest evidence based on gene count, statistical significance, functional coherence, and literature support. Programs 4-5 are less robust due to mechanistic heterogeneity, technical inconsistencies, and limited external validation. The absence of independent cohort replication is the major limitation across all programs.

The analysis integrates 100 genes with 699 PubMed and 866 Europe PMC articles, pathway annotations from Reactome/GO/KEGG, protein interactions from STRING/IntAct/OmniPath, tissue expression from GTEx/HPA, and clinical annotations from ClinVar/ClinicalTrials/cBioPortal. All 100 selected genes have at least one annotation record, though coverage varies by source (19-100 genes per database).

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=46, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Anthropic / claude-opus-4-8

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
